PULUODY PLD-MPCS2.0 Microscopic Imaging System for Insoluble Particle Counting in Pharmaceuticals

Overview

The PULUODY PLD-MPCS2.0 Microscopic Imaging System for Insoluble Particle Counting is a regulatory-compliant, image-based analytical platform engineered for quantitative morphological and dimensional characterization of insoluble particulate matter in parenteral pharmaceuticals and high-purity liquids. It implements the Microscopic Particle Counting Method specified in Chinese Pharmacopoeia (ChP) General Chapter 0903 Method 2 — fully aligned with USP , USP , EP 8.0, JP 16, and ISO 21501-4 Annex D. Unlike light-blockage (light obscuration) instruments, this system captures high-fidelity optical images of particles retained on membrane filters, enabling direct visualization, morphometric classification (e.g., aspect ratio, circularity), and statistically robust enumeration across a 1–500 µm measurement range. Its core architecture integrates a precision biological microscope, a calibrated 3-megapixel monochrome CCD camera, motorized XY stage with automated membrane scanning, and a validated software suite designed to support GLP/GMP workflows.

Key Features

• Regulatory-grade optical imaging platform compliant with ChP 0903 Method 2, USP , and ISO 21501-4 for insoluble particle testing
• Motorized, fully automated membrane scanning with sub-micron positional accuracy and seamless digital image stitching
• Calibrated optical path delivering 0.1 µm resolution and verified measurement repeatability (<5% RSD, excluding sample preparation variability)
• Dual-mode operation: manual focus and illumination control (required for cleanliness-sensitive applications) plus auto-capture and auto-analysis sequences
• Comprehensive particle morphology analysis — including size distribution, aspect ratio distribution, circularity histogram, and Feret diameter statistics
• Integrated operator management system with role-based access control, electronic signatures, and full audit trail per FDA 21 CFR Part 11 requirements
• Configurable particle classification logic: user-defined size bins, shape thresholds, and ISO/NAS grading rules embedded directly into reporting templates

Sample Compatibility & Compliance

The PLD-MPCS2.0 supports standardized filtration protocols for aqueous and non-aqueous liquid samples per ICH Q5C, USP , and ChP 2020. Validated applications include sterile injectables (solution, lyophilized powder, concentrated solutions), ophthalmic preparations, vaccines, WFI, medical device extracts (per GB 8368), and infusion set filtrates. The system accommodates standard 25 mm or 47 mm mixed-cellulose-ester (MCE) or polycarbonate membranes. All calibration procedures follow traceable reference standards certified by Northwest Metrology Testing Center (civilian sector). Full compliance documentation includes verification reports for magnification linearity, pixel-to-micron conversion, segmentation fidelity (>93% success rate), and counting accuracy (±3% typical, per ChP 2020 validation protocol).

Software & Data Management

The proprietary PULUODY ParticleVision™ software (Windows XP/2000 compatible) provides a secure, configurable environment for method development, data acquisition, and report generation. It features embedded test templates aligned with pharmacopoeial monographs (e.g., USP Table 1 limits, ChP 2020 acceptance criteria), automatic grade assignment, and customizable PDF/Excel export with embedded metadata (operator ID, timestamp, instrument ID, filter lot, environmental conditions). Data integrity safeguards include immutable audit logs, electronic signature capture, and password-protected method locking. Raw image archives are stored with hash-verified integrity; all processed results retain full traceability to original frames and calibration records.

Applications

• Pharmaceutical QC/QA: Routine batch release testing of injectables, raw materials, and container-closure systems per GMP Annex 1 and WHO TRS 961
• Process development: Evaluation of filtration efficiency, leachables from tubing or stoppers, and particulate generation during filling operations
• Medical device validation: Quantitative assessment of particulate shedding from syringes, IV sets, and dialysis membranes per ISO 8536-4 and ISO 8536-6
• High-purity water monitoring: Electronic-grade water (ASTM D5127), ultrapure water (SEM FSI 12-17), and clean steam condensate analysis
• Advanced materials: CMP slurry qualification, nanomaterial dispersion stability, and semiconductor wafer rinse water certification
• Cross-industry contamination control: Hydraulic fluid cleanliness (ISO 4406), lubricant particulate load, and cosmetic emulsion stability screening

FAQ

Does the PLD-MPCS2.0 comply with FDA 21 CFR Part 11 requirements for electronic records and signatures?

Yes — the software enforces role-based access, electronic signatures with reason-for-use annotation, and immutable audit trails for all critical actions including method changes, result approvals, and calibration events.
Can the system be validated for use in a regulated GMP environment?

Yes — IQ/OQ/PQ documentation packages, traceable calibration certificates, and protocol templates for ChP/USP/ISO alignment are available upon request.
Is particle identification (e.g., fiber vs. crystal) supported?

Morphological descriptors (aspect ratio, convexity, solidity) enable preliminary classification; definitive material identification requires coupling with micro-FTIR or Raman, which the system’s image metadata supports via export tagging.
What filtration methods are recommended for USP testing?

The system is optimized for pressure-driven vacuum filtration using 0.45 µm MCE membranes per USP Section 3. Filter selection, wetting agents, and rinsing volumes must follow site-specific SOPs validated per ICH Q5C.
How is system suitability verified prior to sample analysis?

Daily verification uses NIST-traceable latex sphere suspensions (e.g., 10 µm and 25 µm) to confirm sizing accuracy, segmentation reliability, and counting linearity across the operational range.